{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:00Z","timestamp":1792725060184,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine. The peptide is elevated during interictal and ictal migraine and it might be a biomarker for the disease. However, CGRP detection in blood is limited by dilution and rapid degradation. Therefore, we investigated tear fluid CGRP during spontaneous migraine attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Episodic migraine patients were investigated at two study days. At study day 1, tear fluid was sampled interictally (\u2018interictal\u2019) and a thorough migraine history was conducted. At study day 2, participants were investigated during a spontaneous migraine attack. Participants were asked to call the study team when experiencing a migraine attack and to present to the outpatient headache center. After arrival, tear fluid was sampled and headache characteristics were assessed. Tear fluid CGRP levels at maximum headache intensity (\u2018headache\u2019) and after headache improvement (\u2018post headache\u2019) were analyzed using a commercial CGRP ELISA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      14 female migraine patients (28.4\u2009\u00b1\u20099.3 years) were included in the analysis. At the time of maximum headache, tear fluid CGRP levels were significantly higher compared to CGRP levels at baseline and after headache resolution (\u2018interictal\u2019: 1.89\u2009\u00b1\u20091.68 ng\/ml, headache: 2.34\u2009\u00b1\u20092.20 ng\/ml, post headache: 1.23\u2009\u00b1\u20090.80 ng\/ml;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). The rise of tear fluid CGRP levels was significantly higher if time since headache onset was shorter (0\u20133\u00a0h: +1.80\u2009\u00b1\u20091.18 ng\/ml, 3\u20136\u00a0h: +0.13\u2009\u00b1\u20090.93 ng\/ml, &gt; 6\u00a0h: -1.15\u2009\u00b1\u20091.63 ng\/ml;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tear fluid CGRP levels are elevated during spontaneous migraine attacks, suggesting that the detection of CGRP in tear fluid is valid and might be a migraine biomarker in future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02255-1","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T10:13:30Z","timestamp":1766657610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tear fluid calcitonin gene-related peptide (CGRP) is elevated during spontaneous migraine attacks \u2013 results from a pilot study"],"prefix":"10.1186","volume":"27","author":[{"given":"Katharina","family":"Kamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Brandi-Dohrn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2255_CR1","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, (2018) 38(1): pp. 1-211 https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"2255_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2302\/kjm.60.82","volume":"60","author":"K Messlinger","year":"2011","unstructured":"Messlinger K, Fischer MJM, Lennerz JK (2011) Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med 60(3):82\u201389. https:\/\/doi.org\/10.2302\/kjm.60.82","journal-title":"Keio J Med"},{"key":"2255_CR3","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","volume":"154","author":"R Noseda","year":"2013","unstructured":"Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain 154:S44\u2013S53. https:\/\/doi.org\/10.1016\/j.pain.2013.07.021","journal-title":"Pain"},{"issue":"4","key":"2255_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA et al (2014) Calcitonin Gene-Related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099\u20131142. https:\/\/doi.org\/10.1152\/physrev.00034.2013","journal-title":"Physiol Rev"},{"key":"2255_CR5","doi-asserted-by":"publisher","unstructured":"Dodick DW (2018) A Phase-by-Phase Review of Migraine Pathophysiology. Headache: The Journal of Head and Face Pain, 58(S1): pp. 4\u201316 https:\/\/doi.org\/10.1111\/head.13300","DOI":"10.1111\/head.13300"},{"issue":"1","key":"2255_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-024-01769-4","volume":"25","author":"G G\u00e1rate","year":"2024","unstructured":"G\u00e1rate G et al (2024) Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience. J Headache Pain 25(1):69. https:\/\/doi.org\/10.1186\/s10194-024-01769-4","journal-title":"J Headache Pain"},{"key":"2255_CR7","doi-asserted-by":"publisher","unstructured":"Kamm K (2022 DOI) CGRP and migraine: what have we learned from measuring CGRP in migraine patients so far? Frontiers in Neurology, 2022. 13. https:\/\/doi.org\/10.3389\/fneur.2022.930383","DOI":"10.3389\/fneur.2022.930383"},{"issue":"13","key":"2255_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1177\/03331024211024161","volume":"41","author":"K Messlinger","year":"2021","unstructured":"Messlinger K et al (2021) CGRP measurements in human plasma \u2013 a methodological study. Cephalalgia 41(13):1359\u20131373. https:\/\/doi.org\/10.1177\/03331024211024161","journal-title":"Cephalalgia"},{"issue":"3","key":"2255_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/03331024211040467","volume":"42","author":"A Alpuente","year":"2022","unstructured":"Alpuente A et al (2022) Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia 42(3):186\u2013196. https:\/\/doi.org\/10.1177\/03331024211040467","journal-title":"Cephalalgia"},{"issue":"2","key":"2255_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/head.12250","volume":"54","author":"R Cady","year":"2014","unstructured":"Cady R et al (2014) An exploratory study of salivary calcitonin Gene-Related peptide levels relative to acute interventions and preventative treatment with OnabotulinumtoxinA in chronic migraine. Headache: J Head Face Pain 54(2):269\u2013277. https:\/\/doi.org\/10.1111\/head.12250","journal-title":"Headache: J Head Face Pain"},{"issue":"1","key":"2255_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s10194-025-02141-w","volume":"26","author":"K Kamm","year":"2025","unstructured":"Kamm K et al (2025) Tear fluid CGRP rises during Glyceryl trinitrate-induced headache in migraine patients. J Headache Pain 26(1):260. https:\/\/doi.org\/10.1186\/s10194-025-02141-w","journal-title":"J Headache Pain"},{"issue":"12","key":"2255_CR12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1177\/0333102419856640","volume":"39","author":"K Kamm","year":"2019","unstructured":"Kamm K, Straube A, Ruscheweyh R (2019) Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 39(12):1535\u20131543. https:\/\/doi.org\/10.1177\/0333102419856640","journal-title":"Cephalalgia"},{"issue":"1","key":"2255_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-020-01134-1","volume":"21","author":"JCA Edvinsson","year":"2020","unstructured":"Edvinsson JCA et al (2020) The fifth cranial nerve in headaches. J Headache Pain 21(1):65. https:\/\/doi.org\/10.1186\/s10194-020-01134-1","journal-title":"J Headache Pain"},{"issue":"5","key":"2255_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1046\/j.1468-29821995.1505384.x","volume":"15","author":"V Gallai","year":"1995","unstructured":"Gallai V et al (1995) Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15(5):384\u2013390","journal-title":"Cephalalgia"},{"issue":"1","key":"2255_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"issue":"3","key":"2255_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","volume":"26","author":"P Sarchielli","year":"2006","unstructured":"Sarchielli P et al (2006) Clinical-Biochemical correlates of migraine attacks in Rizatriptan responders and Non-Responders. Cephalalgia 26(3):257\u2013265. https:\/\/doi.org\/10.1111\/j.1468-2982.2005.01016.x","journal-title":"Cephalalgia"},{"issue":"6","key":"2255_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/0333102409351807","volume":"30","author":"L Edvinsson","year":"2010","unstructured":"Edvinsson L, Ekman R, Goadsby PJ (2010) Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia 30(6):761\u2013766. https:\/\/doi.org\/10.1177\/0333102409351807","journal-title":"Cephalalgia"},{"issue":"10","key":"2255_CR18","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/head.15011","volume":"65","author":"ML Garelja","year":"2025","unstructured":"Garelja ML, Rees TA, Hay DL (2025) Calcitonin gene-related peptide and headache: comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays. Headache: J Head Face Pain 65(10):1744\u20131753. https:\/\/doi.org\/10.1111\/head.15011","journal-title":"Headache: J Head Face Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02255-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:53:58Z","timestamp":1769518438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02255-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2255"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02255-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8216015\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katharina Kamm has received travel grants and\/ or honoraria from Lundbeck, TEVA and Novartis. Annika Brandi-Dohrn has no conflicting interests. Andreas Straube has received travel grants and\/or honoraria from Allergan\/AbbVie, Hormosan, Lilly, Lundbeck, Novartis, Sanofi and Teva. Stefanie F\u00f6rderreuther has received travel grants and\/or honoraria for lectures or advisory boards from TEVA, Lundbeck, Abbvie, Novartis, Hormosan. Ruth Ruscheweyh has received travel grants and\/or honoraria for lectures or advisory boards, or has con-sulted for AbbVie, Betapharm, Lundbeck, Novartis, Pfizer and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}